During the past decade, RPS Infectious Diseases conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "RPS Infectious Diseases" are "Acute Bacterial Skin and Skin Structure Infections" (1 trials), "Clostridium Infections" (1 trials), "Diarrhea" (1 trials) and "HIV Infections" (1 trials). Many other conditions were trialed in "RPS Infectious Diseases" in a lesser frequency.

Most popular intervention types in "RPS Infectious Diseases" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Linezolid" (1 trials), "NXL103" (1 trials), "Rifaximin (Xifaxan)" (1 trials), "Vancomycin" (1 trials) and "maraviroc" (1 trials). Other intervention names were less common.

The vast majority of trials in "RPS Infectious Diseases" are 3 trials for "All" genders.

Currently, there are NaN active trials in "RPS Infectious Diseases". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in RPS Infectious Diseases, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in RPS Infectious Diseases, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".